Samenvatting
Despite the success of drug discovery over the past decades, many potential drug targets still remain intractable for small molecule modulation. The development of proteolysis targeting chimeras (PROTACs) that trigger degradation of the target proteins provides a conceptually novel approach to address drug targets that remained previously elusive. Currently, the main challenge of PROTAC development is the identification of efficient, tissue- and cell-selective PROTAC molecules with good drug-likeness and favorable safety profiles. This review focuses on strategies to enhance the effectiveness and selectivity of PROTACs. We provide a comprehensive summary of recently reported PROTAC design strategies and discuss the advantages and disadvantages of these strategies. Future perspectives for PROTAC design will also be discussed.
Originele taal-2 | English |
---|---|
Pagina's (van-tot) | 710-723 |
Aantal pagina's | 14 |
Tijdschrift | ACS Pharmacology & Translational Science |
Volume | 5 |
Nummer van het tijdschrift | 9 |
DOI's | |
Status | Published - 2022 |